Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer

Kristina R. Dahlstrom, Karen Anderson, Matthew S. Field, Diego Chowell, Jing Ning, Nan Li, Qingyi Wei, Guojun Li, Erich M. Sturgis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Because of the current epidemic of human papillomavirus (HPV)–related oropharyngeal cancer (OPC), a screening strategy is urgently needed. The presence of serum antibodies to HPV-16 early (E) antigens is associated with an increased risk for OPC. The purpose of this study was to evaluate the diagnostic accuracy of antibodies to a panel of HPV-16 E antigens in screening for OPC. METHODS: This case-control study included 378 patients with OPC, 153 patients with nonoropharyngeal head and neck cancer (non-OPC), and 782 healthy control subjects. The tumor HPV status was determined with p16 immunohistochemistry and HPV in situ hybridization. HPV-16 E antibody levels in serum were identified with an enzyme-linked immunosorbent assay. A trained binary logistic regression model based on the combination of all E antigens was predefined and applied to the data set. The sensitivity and specificity of the assay for distinguishing HPV-related OPC from controls were calculated. Logistic regression analysis was used to calculate odds ratios with 95% confidence intervals for the association of head and neck cancer with the antibody status. RESULTS: Of the 378 patients with OPC, 348 had p16-positive OPC. HPV-16 E antibody levels were significantly higher among patients with p16-positive OPC but not among patients with non-OPC or among controls. Serology showed high sensitivity and specificity for HPV-related OPC (binary classifier: 83% sensitivity and 99% specificity for p16-positive OPC). CONCLUSIONS: A trained binary classification algorithm that incorporates information about multiple E antibodies has high sensitivity and specificity and may be advantageous for risk stratification in future screening trials. Cancer 2017;123:4886-94.

Original languageEnglish (US)
Pages (from-to)4886-4894
Number of pages9
JournalCancer
Volume123
Issue number24
DOIs
StatePublished - Dec 15 2017

Fingerprint

Oropharyngeal Neoplasms
Human papillomavirus 16
Antigens
Antibodies
Serum
Sensitivity and Specificity
Logistic Models
Head and Neck Neoplasms
Neoplasms
Serology
Early Detection of Cancer
In Situ Hybridization
Case-Control Studies
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Odds Ratio
Regression Analysis
Confidence Intervals

Keywords

  • head and neck neoplasms
  • human papillomavirus
  • oropharyngeal cancer
  • papillomavirus oncogene proteins
  • serum antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer. / Dahlstrom, Kristina R.; Anderson, Karen; Field, Matthew S.; Chowell, Diego; Ning, Jing; Li, Nan; Wei, Qingyi; Li, Guojun; Sturgis, Erich M.

In: Cancer, Vol. 123, No. 24, 15.12.2017, p. 4886-4894.

Research output: Contribution to journalArticle

Dahlstrom, Kristina R. ; Anderson, Karen ; Field, Matthew S. ; Chowell, Diego ; Ning, Jing ; Li, Nan ; Wei, Qingyi ; Li, Guojun ; Sturgis, Erich M. / Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer. In: Cancer. 2017 ; Vol. 123, No. 24. pp. 4886-4894.
@article{c3eacc9c8d044cea973253a254a016b9,
title = "Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer",
abstract = "BACKGROUND: Because of the current epidemic of human papillomavirus (HPV)–related oropharyngeal cancer (OPC), a screening strategy is urgently needed. The presence of serum antibodies to HPV-16 early (E) antigens is associated with an increased risk for OPC. The purpose of this study was to evaluate the diagnostic accuracy of antibodies to a panel of HPV-16 E antigens in screening for OPC. METHODS: This case-control study included 378 patients with OPC, 153 patients with nonoropharyngeal head and neck cancer (non-OPC), and 782 healthy control subjects. The tumor HPV status was determined with p16 immunohistochemistry and HPV in situ hybridization. HPV-16 E antibody levels in serum were identified with an enzyme-linked immunosorbent assay. A trained binary logistic regression model based on the combination of all E antigens was predefined and applied to the data set. The sensitivity and specificity of the assay for distinguishing HPV-related OPC from controls were calculated. Logistic regression analysis was used to calculate odds ratios with 95{\%} confidence intervals for the association of head and neck cancer with the antibody status. RESULTS: Of the 378 patients with OPC, 348 had p16-positive OPC. HPV-16 E antibody levels were significantly higher among patients with p16-positive OPC but not among patients with non-OPC or among controls. Serology showed high sensitivity and specificity for HPV-related OPC (binary classifier: 83{\%} sensitivity and 99{\%} specificity for p16-positive OPC). CONCLUSIONS: A trained binary classification algorithm that incorporates information about multiple E antibodies has high sensitivity and specificity and may be advantageous for risk stratification in future screening trials. Cancer 2017;123:4886-94.",
keywords = "head and neck neoplasms, human papillomavirus, oropharyngeal cancer, papillomavirus oncogene proteins, serum antibodies",
author = "Dahlstrom, {Kristina R.} and Karen Anderson and Field, {Matthew S.} and Diego Chowell and Jing Ning and Nan Li and Qingyi Wei and Guojun Li and Sturgis, {Erich M.}",
year = "2017",
month = "12",
day = "15",
doi = "10.1002/cncr.30955",
language = "English (US)",
volume = "123",
pages = "4886--4894",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "24",

}

TY - JOUR

T1 - Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer

AU - Dahlstrom, Kristina R.

AU - Anderson, Karen

AU - Field, Matthew S.

AU - Chowell, Diego

AU - Ning, Jing

AU - Li, Nan

AU - Wei, Qingyi

AU - Li, Guojun

AU - Sturgis, Erich M.

PY - 2017/12/15

Y1 - 2017/12/15

N2 - BACKGROUND: Because of the current epidemic of human papillomavirus (HPV)–related oropharyngeal cancer (OPC), a screening strategy is urgently needed. The presence of serum antibodies to HPV-16 early (E) antigens is associated with an increased risk for OPC. The purpose of this study was to evaluate the diagnostic accuracy of antibodies to a panel of HPV-16 E antigens in screening for OPC. METHODS: This case-control study included 378 patients with OPC, 153 patients with nonoropharyngeal head and neck cancer (non-OPC), and 782 healthy control subjects. The tumor HPV status was determined with p16 immunohistochemistry and HPV in situ hybridization. HPV-16 E antibody levels in serum were identified with an enzyme-linked immunosorbent assay. A trained binary logistic regression model based on the combination of all E antigens was predefined and applied to the data set. The sensitivity and specificity of the assay for distinguishing HPV-related OPC from controls were calculated. Logistic regression analysis was used to calculate odds ratios with 95% confidence intervals for the association of head and neck cancer with the antibody status. RESULTS: Of the 378 patients with OPC, 348 had p16-positive OPC. HPV-16 E antibody levels were significantly higher among patients with p16-positive OPC but not among patients with non-OPC or among controls. Serology showed high sensitivity and specificity for HPV-related OPC (binary classifier: 83% sensitivity and 99% specificity for p16-positive OPC). CONCLUSIONS: A trained binary classification algorithm that incorporates information about multiple E antibodies has high sensitivity and specificity and may be advantageous for risk stratification in future screening trials. Cancer 2017;123:4886-94.

AB - BACKGROUND: Because of the current epidemic of human papillomavirus (HPV)–related oropharyngeal cancer (OPC), a screening strategy is urgently needed. The presence of serum antibodies to HPV-16 early (E) antigens is associated with an increased risk for OPC. The purpose of this study was to evaluate the diagnostic accuracy of antibodies to a panel of HPV-16 E antigens in screening for OPC. METHODS: This case-control study included 378 patients with OPC, 153 patients with nonoropharyngeal head and neck cancer (non-OPC), and 782 healthy control subjects. The tumor HPV status was determined with p16 immunohistochemistry and HPV in situ hybridization. HPV-16 E antibody levels in serum were identified with an enzyme-linked immunosorbent assay. A trained binary logistic regression model based on the combination of all E antigens was predefined and applied to the data set. The sensitivity and specificity of the assay for distinguishing HPV-related OPC from controls were calculated. Logistic regression analysis was used to calculate odds ratios with 95% confidence intervals for the association of head and neck cancer with the antibody status. RESULTS: Of the 378 patients with OPC, 348 had p16-positive OPC. HPV-16 E antibody levels were significantly higher among patients with p16-positive OPC but not among patients with non-OPC or among controls. Serology showed high sensitivity and specificity for HPV-related OPC (binary classifier: 83% sensitivity and 99% specificity for p16-positive OPC). CONCLUSIONS: A trained binary classification algorithm that incorporates information about multiple E antibodies has high sensitivity and specificity and may be advantageous for risk stratification in future screening trials. Cancer 2017;123:4886-94.

KW - head and neck neoplasms

KW - human papillomavirus

KW - oropharyngeal cancer

KW - papillomavirus oncogene proteins

KW - serum antibodies

UR - http://www.scopus.com/inward/record.url?scp=85037055636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037055636&partnerID=8YFLogxK

U2 - 10.1002/cncr.30955

DO - 10.1002/cncr.30955

M3 - Article

C2 - 28898394

AN - SCOPUS:85037055636

VL - 123

SP - 4886

EP - 4894

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 24

ER -